Ginkgo Bioworks Holdings Total Assets
Ginkgo Bioworks Holdings total assets. Based on the latest financial reports, Ginkgo Bioworks Holdings (DNA) holds total assets worth $990.05 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ginkgo Bioworks Holdings market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Ginkgo Bioworks Holdings (2019–2025)
Total assets of Ginkgo Bioworks Holdings from 2019 to 2025. This chart illustrates how Ginkgo Bioworks Holdings's total assets have evolved over time, based on quarterly financial data. See Ginkgo Bioworks Holdings (DNA) share price today for real-time trading data and today's change.
Ginkgo Bioworks Holdings - Asset Composition Analysis
Ginkgo Bioworks Holdings Total Assets Breakdown (December 2025)
Ginkgo Bioworks Holdings total assets breakdown as of December 2025. Ginkgo Bioworks Holdings's total assets of $990.05 Million consist of 42.1% current assets and 57.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $167.20 Million | 14.9% |
| Accounts Receivable | $24.03 Million | 2.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $528.70 Million | 47.2% |
| Intangible Assets | $56.92 Million | 5.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Ginkgo Bioworks Holdings's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Ginkgo Bioworks Holdings (DNA) working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ginkgo Bioworks Holdings's current assets represent 42.1% of total assets in 2025, a decrease from 73.4% in 2019.
- Cash Position: Cash and equivalents constituted 14.9% of total assets in 2025, down from 71.0% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is property, plant & equipment at 47.2% of total assets.
Ginkgo Bioworks Holdings Competitors by Total Assets
Key competitors of Ginkgo Bioworks Holdings based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
Ginkgo Bioworks Holdings - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.57 | 5.41 | 20.05 |
| Quick Ratio | 4.57 | 5.41 | 20.01 |
| Cash Ratio | 0.00 | 2.10 | 19.26 |
| Working Capital | $259.80 Million | $426.31 Million | $1.72 Billion |
Ginkgo Bioworks Holdings - Advanced Valuation Insights
This section examines the relationship between Ginkgo Bioworks Holdings's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.37 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | -18.7% |
| Total Assets | $1.12 Billion |
| Market Capitalization | $625.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ginkgo Bioworks Holdings's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ginkgo Bioworks Holdings's assets decreased by 18.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ginkgo Bioworks Holdings (2019–2025)
The table below shows the annual total assets of Ginkgo Bioworks Holdings from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.12 Billion | -18.71% |
| 2024-12-31 | $1.38 Billion | -17.29% |
| 2023-12-31 | $1.67 Billion | -34.42% |
| 2022-12-31 | $2.54 Billion | +22.61% |
| 2021-12-31 | $2.07 Billion | +206.74% |
| 2020-12-31 | $675.15 Million | -3.18% |
| 2019-12-31 | $697.32 Million | -- |
About Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artific… Read more